Ingested type I interferon: State of the art as treatment for autoimmunity

Experimental Biology and Medicine

Volumn 227, Issue 11, 2002, Pages 981-988

  Brod, Staley A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; GALT; Multiple sclerosis; Protein ingestion; Type 1 diabetes; Type I interferon

Indexed keywords

ALPHA INTERFERON; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; AZATHIOPRINE; CONTRAST MEDIUM; CYCLOSPORIN; CYTOKINE; GADOLINIUM; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INSULIN; INTERFERON BETA SERINE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 8; MESSENGER RNA; METHOTREXATE; NICOTINAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; SALAZOSULFAPYRIDINE; STAT1 PROTEIN; SUCRALFATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; GRAFT REJECTION; HUMAN; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LOZENGE; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ISLET TRANSPLANTATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SINGLE BLIND PROCEDURE; SJOEGREN SYNDROME; TREATMENT OUTCOME;

ANIMALIA;

EID: 0036913590     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020222701105     Document Type: Short Survey

References (100)

1. Brod SA. Hypothesis: Multiple sclerosis is a type I interferon deficiency syndrome. Proc Soc Exp Biol Med 218:278-283, 1998.
2. Brod SA. Gut response. Therapy with ingested immunomodulatory proteins. Arch Neurol 54:1300-1302, 1997.
3. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action (In Process Citation). J Interferon Cytokine Res 19:817-828, 1999.
4. Bocci V. Is interferon effective after oral administration? J Biol Reg Homeostasis Agents 4:81-83, 1990.
5. Wolinsky J. Multiple sclerosis. In: Appel S, Ed. Current Neurology. New York: Mosby Year Book, Inc, pp167-207, 1993.
6. McFarlin D, McFarland H. Multiple sclerosis. N Eng J Med 307:1183-1188, 1982.
7. Antel JP, Arnason BGW, Medof ME. Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity. Ann Neurol 5:338-342, 1979.
8. Group TIMSS. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661, 1993.
9. Jacobs L, Cookfair D, Rudick R, Herndon R, Richert J, Salazar A, Fischer J, Granger C, Simon J, Goodkin D, Granger C, Simon J, Alam J, Bartoszak D, Bourdette D, Braiman J, Brownscheidle C, Coats M, Cohan S, Dougherty D, Kinkel R, Mass M, Munschauer F, Priore R, Pullicino P, Scherokman B, Whitham R. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294, 1994.
10. Myhr KM, Riise T, Green Lilleas FE, Beiske TG, Celius EG, Edland A, Jensen D, Larsen JP, Nilsen R, Nortvedt MW, Smievoll AI, Vedeler C, Nyland HI. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology 52:1049-1056, 1999.
11. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, Bergamini L, Bergamasco B. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44:406-413, 1994.
12. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol 46:850-859, 1999.
13. Losseff NA, Kingsley DP, McDonald WI, Miller DH, Thompson AJ. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler 1:218-222, 1996.
14. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (see comments). Neurology 45:1277-1285, 1995.
15. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology 47:889-894, 1996.
16. Brod SA, Marshall GD Jr, Henninger EM, Sriram S, Khan M, Wolinsky JS. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology 46:1633-1638, 1996.
17. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: A 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29:267-274, 1986.
18. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recentonset insulin-dependent diabetes mellitus. N Engl J Med 319:599-604, 1988.
19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. (see comments). N Engl J Med 329:977-986, 1993.
20. Shah S, Malone J, Simpson N. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 320:550-554, 1989.
21. Anonymous. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 37:1574-1582, 1988.
22. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A. Cyclosporin increases the rate and length of remissions in insulin-dependen T diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2:119-124, 1986.
23. Bougneres P, Landais P, Boisson C, Carel J, Frament N, Boitard C, Chaussain J, Bach J. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39:1264-1272, 1990.
24. Cook J, Hudson I, Harrison L, Dean B, Colman P, Werther G, Warne G, Court J. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 38:779-783, 1989.
25. Chase H, Butler-Simon N, Garg S, McDuffie M, Hoops S, O'Brien D, A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33:444-446, 1990.
26. Lewis C, Canafax D, Sprafka J, Barbosa J. Double-blind randomized trial of nicotinamide on early-onset diabetes. Diabetes Care 15:121-123, 1992.
27. Pozzilli P, Visalli N, Signore A, Baroni M, Buzzetti R, Cavallo M, Boccuni M, Fava D, Gragnoli C, Andreani D, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 38:848-852, 1995.
28. Hochberg MC. Adult and juvenile rheumatoid arthritis: Current epidemiologic concepts. Epidemiol Rev 3:27-44, 1981.
29. Scott DL, Symmons DP, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: Results after 20 years. Lancet 1:1108-1111, 1987.
30. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 120:26-34, 1994.
31. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. Arthritis Rheum 37:481-494, 1994.
32. O'Dell JR, Haire CE, Palmer W, Drymalski W, Wees S, Blakely K, Churchill M, Eckhoff PJ, Weaver A, Doud D, Erikson N, Dietz F, Olson R, Maloley P, Klassen LW, Moore GF. Treatment of early rheumatoid arthritis with minocycline or placebo: Results of a randomized, double-blind, placebo-controlled trial (see comments). Arthritis Rheum 40:842-848, 1997.
33. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17:994-1002, 1990.
34. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice (published erratum appears in J Rheumatol 1992 Dec;19(12):1998). J Rheumatol 19:704-708, 1992.
35. Anonymous. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 39:723-731, 1996.
36. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, van Albada-Kuipers GA, ter Borg EJ, Brus HL, Dinant HJ, Kruize AA, Schenk Y. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial (see comments). Ann Intern Med 124:699-707, 1996.
37. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woodey JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105-1110, 1994.
38. Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 2:706-709, 1988.
39. Kahle P, Saal J, Schaudt K, Zacher J, Fritz P, Pawelec G. Determination of cytokines in synovial fluids: Correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann Rheum Dis 51:731-734, 1992.
40. Shore A, Jaglal S, Keystone EC. Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol 65:293-302, 1986.
41. Canete JD, Llena J, Collado A, Sanmarti R, Gaya A, Gratacos J, Blay M, Munoz-Gomez J. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 36:38-42, 1997.
42. Miyasaka N, Sato K, Goto M, Sasano M, Natsuyama M, Inoue K, Nishioka K. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction. Arthritis Rheum 31:480-486, 1988.
43. Sasaki K, Hattori T, Fujisawa T, Takahashi K, Inoue H, Takigawa M. Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J Biochem 123:431-439, 1998.
44. Seitz M, Loetscher P, Dewald B, Towbin H, Baggiolini M. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. J Rheumatol 24:1471-1476, 1997.
45. Isaacs A, Lindenmann J. Virus Interference I. The interferon. Proc R Soc Lond [Biol] 147:258-267, 1957.
46. Dron M, Tovey M. Interferon alpha/beta, gene structure and regulation. In: Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR, Hughes TK, Klimpel GR, Niesel DW, Stanton GJ, Trying SK, Eds. Interferon: Principles and Medical Applications. Galveston, TX: UT Press, pp33-45, 1992.
47. Johnson HM, Baron S. Evaluation of the effects of interferon and interferon inducers on the immune response. Pharmacol Ther 1:349-367, 1977.
48. Zoon KC. Human interferons: Structure and function. Interferon 9:1-12, 1987.
49. Rashidbaigi A, Pestka S. Interferons: Protein structure. In: Baron S, Dianzani F, Stanton GJ, Fleischmann WR, Eds. Interferon System. Austin, TX: UT Press, pp149-168, 1987.
50. Uze G, Lutfalla G, Knudson KE. α and β Interferons and their receptor and their friends and relations. J Interferon Cyt Res 15:3-26, 1995.
51. Aguet M, Mogensen KE. Interferon receptors. In: Gresser I, Ed. Interferons. New York: Academic Press, pp1-22, 1983.
52. Rollwagen R, Baqar S. Oral cytokine administration. Immunol Today 17:548-550, 1996.
53. ser. J Interferon Res 12:411-413, 1992.
54. Bocci V. Absorption of cytokines via the oropharyngeal associated lymphoid tissues - Does an unorthodox route improve the therapeutic index of interferon. Clin Pharmacokinet 21:411-417, 1991.
55. Brandtzaeg P. Overview of the mucosal immune system. Curr Topics Microbiol Immunol 146:13-28, 1989.
56. MacDonald TT. Immunosuppression caused by antigen feeding II. Suppressor T cells mask Peyer's patch B cell priming to orally administered antigen. Eur J Immunol 13:138-142, 1983.
57. Mattingly JA. Immunologic suppression after oral administration of antigen. III. Activation of suppressor-inducer cells in the Peyer's patches. Cell Immunol 86:46-52, 1984.
58. Pfeffer LM, Donner DD. The downregulation of IFN-α receptors in human lymphoblastoid cells: Relation of cellular responsiveness to antiproliferative action of IFN-α. Cancer Res 50:2654-2657, 1990.
59. Pfeffer LM, Colamonici OR. Transmembrane signalling by interferon-α. Pharmacol Ther 52:149-151, 1991.
60. Fleischmann WR Jr, Koren S, Fleischmann CM. Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc Soc Exp Biol Med 201:200-207, 1992.
61. Cantell K, Pyhala L. Circulating interferon in rabbits after administration by different routes. J Gen Virol 20:97-104, 1973.
62. Gibson DM, Cotler S, Spiegel HE, Colburn WA. Pharmacokinetics of recombinant leucocyte A interferon following various routes and modes of administration to the dog. J Interferon Res 5:403-408, 1985.
63. Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant leucocyte A interferon following IV infusion and bolus, IM, and PO administration to african green monkeys. J Interferon Res 4:399-409, 1984.
64. Horisberger MA. Mx protein: Function and mechanism of action. In: Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR, Hughes TK, Klimpel GR, Niesel DW, Stanton GJ, Tyring SK, Eds. Interferon: Principles and Medical Applications. Galveston, TX: UT Press, pp215-224, 1992.
65. Roers A, Hochkeppel H, Horisberger M, Hovanessian A, Haller O. MxA gene expression after live virus vaccination: A sensitive marker for endogenous type I interferon. J Infect Dis 169:807-813, 1994.
66. Brod SA, Khan M. Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmunol 9:11-20, 1996.
67. Brod SA, Nelson L, Jin R, Wolinsky JS. Ingested interferon alpha induces Mx mRNA. Cytokine 11:492-499, 1999.
68. Brod SA, Khan M, Bright J, Sriram S, Marshall GD Jr, Henninger EM, Kerman RH, Wolinsky JS. Decreased CD3-mediated interferon-gamma production in relapsing-remitting multiple sclerosis. Ann Neurol 37:546-549, 1995.
69. Brod SA, Khan M, Nelson LD, Decuir B, Malone M, Henninger E. Adoptive transfer from interferon-alpha-fed mice is associated with inhibition of active experimental autoimmune encephalomyelitis by decreasing recipient tumor necrosis factor-alpha secretion. J Immunother 23:235-245, 2000.
70. Brod SA, Scott M, Burns DK, Phillips JT. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J Interferon Cytokine Res 15:115-122, 1995.
71. Brassard DL, Grace MJ, Bordens RW. Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71:565-581, 2002.
72. Xing T, Zhang L, Lu Q, Hou J, Feng X, Luo K. Th1/Th2 type cytokines in hepatitis B patients treated with interferon-alpha. Chin Med J (Engl) 114:921-924, 2001.
73. Monteleone G, Pender SL, Wathen NC, MacDonald TT. Interferon-alpha drives T cell-mediated immunopathology in the intestine. Eur J Immunol 31:2247-2255, 2001.
74. Brod SA, Kerman RH, Nelson LD, Marshall GD Jr, Henninger EM, Khan M, Jin R, Wolinsky JS. Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. Mult Scler 3:1-7, 1997.
75. Isaac C, Li KB, Genton M, Jardine C, Grochowski E, Palmer M, Kastruloff LF, Oger JJ, Paty DW. MS: A serial study using MRI in relapsing patients. Neurology 38:1511-1515, 1988.
76. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. MR imaging in monitoring the treatment of multiple sclerosis: Concerted action guidelines. J Neurol Neurosurg Psychiat 54:683-688, 1991.
77. Paty DW, Oger JJ, Kastruloff LF, Hashimoto SA, Hooge JJ, Eisen AA, Eisen KA, Purves SJ, Low M, Brangjes V, Robertson W, Li DBK. Biologic vs clinical MS. Neurology 39:151-153, 1989.
78. Thompson AJ, Kermode AJ, MacManus DG, Kendall BE, Kingsley DPE, Moseley IF, McDonald WI. Patterns of disease activity in MS: Clinical and MRI study. Br Med J 300:631-634, 1990.
79. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley DPE, Kendall BE, Feinstein A, McDonald WI. Serial gadolinium enhanced MRI in RRMS of varying didease duration. Neurology 42:60-63, 1993.
80. Willoughby EW, Growchowski E, Li DK, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: A second perspective study in relapsing patients. Ann Neurol 25:43-49, 1989.
81. Brod S, Lindsey J, Vriesendorp F, Ahn C, Narayana P, Wolinsky J. Ingested IFN-a: Results of a pilot study in relapsing-remitting multiple sclerosis (RRMS). Neurology 57:845-852, 2001.
82. Brod S, Darcan S, Malone M, Pappolla M, Nelson L. Ingested IFN-α suppresses IDDM in the NOD mouse. Diabetologia 41:1227-1232, 1998.
83. Brod SA, Katz S, Phan T, Stepkowski S. Ingested interferon-alpha prevents allograft islet transplant rejection. Transplantation 69:2162-2166, 2000.
84. Brod S, Orlander P, Lavis V, Brosnan P, Hardin D, Henninger E, Nyugen M, Riley W. Ingested IFN-α prolongs the "honeymoon" period in newly diagnosed type I diabetes mellitus. J Interferon Cyt Res 21:1021-1030, 2001.
85. Leirisalo-Repo M. The present knowledge of the inflammatory process and the inflammatory. Pharmacol Toxicol 75:1-3, 1994.
86. Nishiura H, Tanaka J, Takeya M, Tsukano M, Kambara T, Imamura T. IL-8/NAP-1 is the major T-cell chemoattractant in synovial tissues of rheumatoid arthritis. Clin Immunol & Immunopathol 80:179-184, 1996.
87. Wechsler A, Gordon M, Dendorfer U, LeClair K. Induction of IL-8 expression in T cells uses the CD28 costimulatory pathway. J Immunol 1531:2515-2523, 1994.
88. Schulze-Koops H, Davis LS, Kavanaugh AF, Lipsky PE. Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. Arthritis Rheum 40:639-647, 1997.
89. Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, Healey L, Kaplan S, Liang M, Luthra H, Medsger T, Mitchell D, Neustadt D, Pinels R, Schaller J, Sharp J, Wilder R, Hunder G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988.
90. Brod SA, Friedman AW, Appleyard J, Warner NB, Henninger EM. Ingested IFN-a has biological effects in rheumatoid arthritis. Int J Immunother 16:53, 2001.
91. Daynes RA, Araneo BA, Dowell TA, Huang K, Dudley D. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 171:979-996, 1990.
92. Bocci V. Roles of interferon produced in physiological conditions. A speculative review. Immunology 64:1-9, 1988.
93. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 18:255-262, 1998.
94. Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB. Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: A phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 19:943-951, 1999.
95. Bosìo E, Beilharz MW, Watson MW, Lawson CM. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo (In Process Citation). J Interferon Cytokine Res 19:869-876, 1999.
96. Satoh Y, Kasama K, Kuwabara M, Yimin, Diao HY, Nakajima H, Kohanawa M, Minagawa T. Suppression of late asthmatic response by low-dose oral administration of interferon-beta in the guinea pig model of asthma. J Interferon Cytokine Res 19:887-894, 1999.
97. Fidler I. Regulation of angiogenesisby type I interferon. Eur Cyt Netw 11:96, 2000.
98. Fujimoto M, Naka T, Tsutsui H, Kawazoc Y, Morita Y, Nakagawa R, Narazaki M, Yoshimoto T. STAT-induced STAT-inhibitor-1 (SSI-1) inhibits not only IFN-gamma signaling but also IL4 signaling. Eur Cyt Netw 11:47, 2000.
99. Ogle CK, Guo X. The effects of IL-6 and LPS on the expression of SOCS by enterocytes. Eur Cyt Netw 11:46, 2000.
100. Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 273:35056-35062, 1998.